@article{87e7e60cad6f478b9beda939ca457b8b,
title = "Common Data Elements for National Institute of Mental Health–Funded Translational Early Psychosis Research",
abstract = "The National Institutes of Health has established the PhenX Toolkit as a web-based resource containing consensus measures freely available to the research community. The National Institute of Mental Health (NIMH) has introduced the Mental Health Research Core Collection as part of the PhenX Toolkit and recently convened the PhenX Early Psychosis Working Group to generate the PhenX Early Psychosis Specialty Collection. The Working Group consisted of two complementary panels for clinical and translational research. We review the process, deliberations, and products of the translational research panel. The Early Psychosis Specialty Collection rationale for measure selection as well as additional information and protocols for obtaining each measure are available on the PhenX website (https://www.phenxtoolkit.org). The NIMH strongly encourages investigators to use instruments from the PhenX Mental Health Research Collections in NIMH-funded studies and discourages use of alternative measures to collect similar data without justification. We also discuss some of the potential advances that can be achieved by collecting common data elements across large-scale longitudinal studies of early psychosis.",
keywords = "Cognition, Data element, Early psychosis, Neuroimaging, PhenX, Schizophrenia",
author = "Dost {\"O}ng{\"u}r and Carter, {Cameron S.} and Gur, {Raquel E.} and Diana Perkins and Akira Sawa and Seidman, {Larry J.} and Carol Tamminga and Wayne Huggins and Carol Hamilton",
note = "Funding Information: The PhenX Toolkit was supported by the National Institutes of Health, National Human Genome Research Institute (via Cooperative Agreement U41 HG007050), and National Institute on Drug Abuse. The Early Psychosis Administrative Supplement to the PhenX U41 was supported by the National Institute of Mental Health (Grant No. 3U41HG007050-03S1). D? served on a Scientific Advisory Board for Neurocrine Biosciences in December 2016. CT has served as an ad hoc consultant within the last 2 years to Sunovion Pharmaceuticals, Astellas Pharma, Taisho Pharmaceutical, and Intra-Cellular Therapies; she is on the Clinical Advisory Board of KyNexis. The following authors were on the teams that developed some of the specific measures selected by the Working Group: REG, Computerized Neurocognitive Battery; CSC, AX-Continuous Performance Test and Relational and Item-Specific Encoding Task; and LJS, Auditory Continuous Performance Test. The protocols for obtaining other specific measures have been provided by the following authors: CSC, protocol for functional magnetic resonance imaging, and D?, protocol for diffusion tensor imaging and magnetic resonance spectroscopy. Note that these latter measures have been developed by large numbers of investigators in the field over decades. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: The PhenX Toolkit was supported by the National Institutes of Health , National Human Genome Research Institute (via Cooperative Agreement U41 HG007050 ), and National Institute on Drug Abuse . The Early Psychosis Administrative Supplement to the PhenX U41 was supported by the National Institute of Mental Health (Grant No. 3U41HG007050-03S1 ). Publisher Copyright: {\textcopyright} 2019 Society of Biological Psychiatry",
year = "2020",
month = jan,
doi = "10.1016/j.bpsc.2019.06.009",
language = "English (US)",
volume = "5",
pages = "10--22",
journal = "Biological Psychiatry: Cognitive Neuroscience and Neuroimaging",
issn = "2451-9022",
publisher = "Elsevier Inc.",
number = "1",
}